Plain-English translation of NCT07489287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing GB-5267, a new treatment made from immune cells that have been specially engineered to fight ovarian cancer. The study will start by giving the treatment intravenously (through your vein) to find the safest and most effective dose. Once researchers identify the right dose, they will test whether combining intravenous and intraperitoneal (directly into the abdomen) infusions works even better.
People with platinum-resistant ovarian cancer have very limited treatment options, and existing therapies often stop working. This medication uses advanced cell engineering to help the body's immune system recognize and destroy cancer cells, offering hope for patients who have run out of standard treatment choices.
You likely qualify if…
You likely don't qualify if…
You will have screening visits to confirm you qualify, including blood tests and a tumor biopsy. Once enrolled, you will receive an infusion of the engineered cells, either through your vein alone or combined with an infusion directly into your abdomen (depending on which group you are in and when you enroll). You will have additional biopsies at day 28 and if your cancer progresses, plus regular follow-up visits to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Roswell Park Cancer Institute
Collaborators
Generate Biomedicines
Enrollment target
~33 participants
Started
August 2026
Primary completion
August 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ask RPCI
Roswell Park Comprehensive Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.